Mast Therapeutics

We are a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. We have built our product pipeline through the strategic acquisition of privately-held companies with clinical-stage assets and we currently are focused on developing new therapies for sickle cell disease, a chronic, genetic disorder classified as a rare, or orphan, disease in the United States and European Union, and for heart failure, a condition with a high unmet need for innovative treatment options.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1995
Size (employees)
14 (est)+134%
Mast Therapeutics was founded in 1995 and is headquartered in San Diego, US

Mast Therapeutics Office Locations

Mast Therapeutics has an office in San Diego
San Diego, US (HQ)
500 3611 Valley Centre Dr

Mast Therapeutics Financials and Metrics

Mast Therapeutics Financials

Mast Therapeutics's revenue was reported to be $128 k in FY, 2016
USD

Net income (Q2, 2017)

(11.5 m)

EBIT (Q2, 2017)

(9.3 m)

Market capitalization (13-Dec-2017)

370.9 m

Cash (30-Jun-2017)

61.1 m
Mast Therapeutics's current market capitalization is $370.9 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

128 k

Revenue growth, %

(100%)

R&D expense

12.9 m19.4 m28.3 m20.8 m

General and administrative expense

9.3 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

45 k94 k

R&D expense

3.1 m4.3 m4.8 m5.4 m6 m7.7 m7.3 m7.9 m7.8 m5.1 m1.4 m4.2 m

General and administrative expense

2.2 m2.3 m2.4 m2.5 m3.6 m2.4 m2.5 m2.8 m2.4 m2.1 m1.6 m5.1 m

Operating expense total

5.3 m6.8 m7.2 m7.9 m9.7 m10.2 m9.8 m10.7 m10.2 m7.2 m5.8 m9.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

25.7 m35.8 m23.1 m8.5 m

Inventories

1.1 m1.1 m1.3 m903 k

Current Assets

45.5 m58.4 m42.3 m12.2 m

PP&E

105.7 k188 k226 k99 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

30.2 m29.8 m26.4 m26 m27.9 m21.2 m32.2 m23.5 m24.5 m20.5 m7.8 m61.1 m

Current Assets

49.9 m50.6 m47.6 m44.1 m50.6 m44.8 m51.4 m38.2 m35.8 m28.3 m8.2 m63.7 m

PP&E

115.1 k106.5 k186.3 k185.7 k248 k230 k250 k199 k171 k148 k88 k672 k

Goodwill

3 m3 m3 m3 m3 m3 m3 m3 m3 m3 m3 m28.2 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(21.5 m)(28.7 m)(39.8 m)(36.1 m)

Depreciation and Amortization

39.5 k85 k146 k99 k

Cash From Operating Activities

(17.8 m)(24.6 m)(32.9 m)(37.3 m)

Purchases of PP&E

(46.8 k)(147 k)(165 k)(8 k)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.3 m)(6.4 m)(7.2 m)(7.9 m)(9.6 m)(10.2 m)(9.9 m)(11.2 m)(10.7 m)(8.2 m)(5.9 m)

Depreciation and Amortization

10.1 k11.5 k22.5 k25.8 k30 k37 k38 k32 k30 k24 k11 k

Accounts Payable

1.2 m1.2 m2.3 m2 m2.9 m2.5 m2.3 m1.5 m502 k
Y, 2017

Financial Leverage

1.6 x
Show all financial metrics

Mast Therapeutics Market Value History

Mast Therapeutics's Web-traffic and Trends

Mast Therapeutics Online and Social Media Presence

Mast Therapeutics Company Life and Culture

You may also be interested in